Loading...
•
Jun 30, 2021
Repare Therapeutics Q2 2021 Earnings Report
Repare Therapeutics reported financial results for the second quarter ended June 30, 2021 and provided a business update.
Key Takeaways
Repare Therapeutics announced the dosing of the first patient in its Phase 1b/2 ATTACC trial of RP-3500 and PARP inhibitor combinations, as well as the dosing of the first patient in the RP-6306 Phase 1 clinical trial. The company's cash and cash equivalents, restricted cash, and marketable securities totaled $301.0 million as of June 30, 2021.
Dosed first patient in Phase 1b/2 ATTACC clinical trial of ATR inhibitor RP-3500 and PARP inhibitor combinations.
Planned disclosure of initial monotherapy data from the Phase 1/2 TRESR RP-3500 clinical trial early in 4Q21.
Announced dosing of first patient in RP-6306 Phase 1 clinical trial.
Progressed towards first druggable target option exercise in Bristol Myers Squibb collaboration.
Repare Therapeutics
Repare Therapeutics
Forward Guidance
Repare Therapeutics is focused on the clinical development of its pipeline, research and development programs, and its collaboration with Bristol Myers Squibb.
Positive Outlook
- Clinical development of RP-3500 and RP-6306.
- Research and development programs focused on genomic instability and DNA damage repair.
- Collaboration with Bristol Myers Squibb to discover and develop novel therapeutics.
- Advancement of a Polθ inhibitor program.
- Continued progress in early-stage, pre-clinical programs.
Challenges Ahead
- Impacts of the COVID-19 pandemic on the Company’s business, clinical trials and financial position.
- Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
- Clinical trial site activation or enrollment rates that are lower than expected.
- Changes in expected or existing competition.
- Unexpected litigation or other disputes.